Antitumor effects of Newcastle disease virus hemagglutinin-neuraminidase used as a molecular adjuvant

Abstract

Gene therapy is a potentially powerful tool used in cancer therapy. The strength of immune responses induced by some strategies is usually low, therefore, the development of agents capable of enhancing these responses is highlighted. The authors investigated the potential of an approach based on the hemagglutinin-neuraminidase(HN) of Newcastle disease virus(NDV) as a potential immune adjuvant. It was found that recombinant adenovirus(Ad) infected SGC7901 cells expressing HN exhibited both hemagglutinin(HA) and neuraminidase(NA) activities. It was demonstrated that administration of HN induced higher levels of the effector cytokines TNF-α, IFN-α and IFN-γ and increased natural killer(NK) cell activity. Based on the therapeutic tumor model, the results show that the administration of HN with Apoptin led to improved survival and tumor suppression. In conclusion, this study indicates that HN stimulates innate immune responses to make the activity of NK cells increased, which highlights the potential adjuvant activity of HN in cancer gene therapy.

Keywords

Hemagglutinin-neuraminidase(HN) / Adjuvant / Innate immunity / Natural killer cell / Antitumor immunity

References

[1] Li X., Liu Y., Wen Z. M., Li C., Lu H. J., Tian M. Y., Jin K. S., Sun L. L., Gao P., Yang E. C., Xu X. H., Kan S. F., Wang Z. M., Wang Y. H., Jin N. Y. Mol. Cancer, 2010, 20(9): 10.

[2] Nia J., Galanib I., Cerwenkab A., Schirrmachera V., Fourniera P. Vaccine, 2011, 29(6): 1185.

[3] Nia J., Schirrmachera V., Fourniera P. Vaccine, 2010, 28(42): 6891.

[4] Su J. Q., Chi B. R., Li X., Liu L., Liu L. M., Qi Y. X., Wang Z. Y., Jin N. Y. Chem. Res. Chinese Universities, 2012, 28(3): 465.

[5] Liu L., Wu W. B., Zhu G. Z., Liu L. M., Guan G. F., Jin N. Y., Chi B. R., Li X. Int. J. Mol. Med., 2012, 10: 3892.

[6] Piao B. G., Li X., Sun L. L., Kan S. F., Liu L., Huang H. Y., Yang G. H., Wang Y. H., Wang Z. Y., Sun J. H., Piao Y. F., Jin N. Y. Chem. Res. Chinese Universities, 2011, 27(3): 455.

[7] Lech P. J., Russell S. J. Expert. Rev. Vaccines, 2010, 9(11): 1275.

[8] Scheid A., Choppin P. W. J. Virol., 1973, 11(2): 263.

[9] Liu C., Air G. M. Virology, 1993, 194(1): 403.

[10] Fournier P., Zeng J., von der Lieth C. W., Washburn B., Ahlert T., Schirrmacher V. Int. J. Oncol., 2004, 24(3): 623.

[11] Jarahian M., Watzl C., Fournier P., Arnold A., Djandji D., Zahedi S., Cerwenka A., Paschen A., Schirrmacher V., Momburg F. J. Virol., 2009, 83(16): 8108.

[12] Zeng J., Fournier P., Schirrmacher V. Virology, 2002, 297(1): 19.

[13] McKee A. S., Munks M. W., Marrack P. Immunity, 2007, 27(5): 687.

[14] Zhang X., Yu C., Zhao J., Fu L., Yi S., Liu S., Yu T., Chen W. J. Gene Med., 2007, 9(8): 715.

[15] Lo-Man R., Rueda P., Sedlik C., Deriaud E., Casal I., Leclerc C. Eur. J. Immunol., 1998, 28(4): 1401.

[16] Takahashi H., Takeshita T., Morein B., Putney S., Germain R. N., Berzofsky J. A. Nature, 1990, 344(6269): 873.

[17] Medzhitov R., Janeway C. A. Jr. Curr. Opin. Immunol., 1997, 9(1): 4.

[18] Davis I. D. Immunol. Cell Biol., 2000, 78(3): 179.

[19] Haeryfar S. M. M. Arch. Iranian. Med., 2008, 11(2): 186.

[20] Cheng M., Zhang J., Jiang W., Chen Y. Y., Tian Z. G. Front. Med., 2012, 6(1): 56.

[21] Sutlu T., Alici E. J. Intern. Med., 2009, 266(2): 154.

[22] Bryceson Y. T., March M. E., Ljunggren H. G., Long E. O. Immunol. Rev., 2006, 214(1): 73.

[23] Martín-Fontecha A., Thomsen L. L., Brett S., Gerard C., Lipp M., Lanzavecchia A., Sallusto F. Nat. Immunol., 2004, 5(12): 1260.